Aprea Therapeutics Inc (APRE) Stock Price, Quote & News

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 948 4119

Website: aprea.com

Address:

3805 Old Easton Road, Doylestown, United States

TezBunny Dec. 21 at 7:13 AM

$APRE lets get this sucker into the .80s

0 · Reply

APEDM Dec. 20 at 12:18 AM

$APRE Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing

0 · Reply

NewsAndFilings Dec. 19 at 1:00 PM

Yesterday's Recap: $SJ Engages ICON Capital Group to Explore Strategic Alternatives and Unlock Shareholder Value $APRE CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

0 · Reply

JarvisFlow Dec. 18 at 4:58 PM

HC Wainwright & Co. has adjusted their stance on Aprea Therapeutics ( $APRE ), setting the rating to Buy with a target price of 20 → 5.

0 · Reply

NewsAndFilings Dec. 18 at 3:30 PM

$APRE Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 https://www.globenewswire.com/news-release/2025/12/18/3207703/0/en/Aprea-Therapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-in-2025-and-Outlook-for-2026.html

0 · Reply

MsGrumpy Dec. 18 at 3:16 PM

$APRE Aprea Therapeutics CEO Issues Letter to Shareholders https://www.globenewswire.com/news-release/2025/12/18/3207703/0/en/Aprea-Therapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-in-2025-and-Outlook-for-2026.html

1 · Reply

IN0V8 Dec. 18 at 3:13 PM

$APRE https://www.globenewswire.com/news-release/2025/12/18/3207703/0/en/Aprea-Therapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-in-2025-and-Outlook-for-2026.html

0 · Reply

Giants67 Dec. 18 at 2:57 PM

$APRE highlights the Company’s ongoing clinical progress, operational execution, and plans for 2026. https://www.globenewswire.com/news-release/2025/12/18/3207703/0/en/Aprea-Therapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-in-2025-and-Outlook-for-2026.htm

0 · Reply

TezBunny Dec. 16 at 3:43 PM

$APRE are you ready for the next leg down😂🤣

0 · Reply

Giants67 Dec. 16 at 3:37 PM

$APRE Insider Trading Activity Marc Duey, a director at Aprea Therapeutics bought 21,459 shares of the company on 12-10-2025 for an estimated $24,999.

0 · Reply

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

Dec 9, 2025, 8:30 AM EST - 16 days ago

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Nov 12, 2025, 8:30 AM EST - 6 weeks ago

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Oct 24, 2025, 8:30 AM EDT - 2 months ago

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Oct 15, 2025, 8:00 AM EDT - 2 months ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Oct 14, 2025, 8:00 AM EDT - 2 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Aug 28, 2025, 8:30 AM EDT - 4 months ago

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 4 months ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Jun 25, 2025, 9:00 AM EDT - 6 months ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

May 14, 2025, 8:00 AM EDT - 8 months ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Mar 31, 2025, 8:30 AM EDT - 9 months ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 25, 2025, 8:30 AM EDT - 9 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 11, 2025, 8:30 AM EDT - 10 months ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Feb 5, 2025, 8:00 AM EST - 11 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Dec 11, 2024, 8:30 AM EST - 1 year ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Sep 9, 2024, 5:15 PM EDT - 1 year ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

May 28, 2024, 8:45 AM EDT - 1 year ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:01 PM EDT - 1 year ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 9:15 AM EDT - 1 year ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Apr 10, 2024, 12:00 PM EDT - 1 year ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Mar 26, 2024, 7:45 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 7:48 AM EDT - 1 year ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:29 AM EDT - 1 year ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 5, 2024, 4:45 PM EST - 1 year ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Feb 6, 2024, 8:01 AM EST - 2 years ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Jan 30, 2024, 8:00 AM EST - 2 years ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Oct 16, 2023, 8:30 AM EDT - 2 years ago

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention

May 15, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

May 8, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

Mar 16, 2023, 8:00 AM EDT - 3 years ago

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting

TezBunny Dec. 21 at 7:13 AM

$APRE lets get this sucker into the .80s

0 · Reply

APEDM Dec. 20 at 12:18 AM

$APRE Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing

0 · Reply

NewsAndFilings Dec. 19 at 1:00 PM

0 · Reply

JarvisFlow Dec. 18 at 4:58 PM

HC Wainwright & Co. has adjusted their stance on Aprea Therapeutics ( $APRE ), setting the rating to Buy with a target price of 20 → 5.

0 · Reply

NewsAndFilings Dec. 18 at 3:30 PM

0 · Reply

MsGrumpy Dec. 18 at 3:16 PM

1 · Reply

IN0V8 Dec. 18 at 3:13 PM

$APRE https://www.globenewswire.com/news-release/2025/12/18/3207703/0/en/Aprea-Therapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-in-2025-and-Outlook-for-2026.html

0 · Reply

Giants67 Dec. 18 at 2:57 PM

0 · Reply

TezBunny Dec. 16 at 3:43 PM

$APRE are you ready for the next leg down😂🤣

0 · Reply

Giants67 Dec. 16 at 3:37 PM

$APRE Insider Trading Activity Marc Duey, a director at Aprea Therapeutics bought 21,459 shares of the company on 12-10-2025 for an estimated $24,999.

0 · Reply

TezBunny Dec. 16 at 8:58 AM

$APRE let’s cut this sucker down

0 · Reply

APEDM Dec. 13 at 2:32 AM

$APRE Their next step should be to prepare RS

0 · Reply

Bulltrader988 Dec. 11 at 7:05 PM

$APRE ...and another Form 4 filled.... Director bought also 👃👀 https://www.sec.gov/Archives/edgar/data/1781983/000110465925120156/xslF345X05/tm2533219-3_4seq1.xml

0 · Reply

Bulltrader988 Dec. 11 at 7:04 PM

$APRE Form 4 filled today .... SrVP/CFO/Prin Fin & Acct Ofcr 👃👀 https://www.sec.gov/Archives/edgar/data/1716213/000110465925120155/xslF345X05/tm2533219-2_4seq1.xml

0 · Reply

APEDM Dec. 11 at 6:21 PM

$APRE Laurence is adept at shorting stock prices, and now they've issued over two million new shares to sell to retail investors.

1 · Reply

SocioCobb Dec. 11 at 2:06 PM

$APRE All of these are open market purchases at 1.17. I'm not in this one but will do some DD.

1 · Reply

Torn891 Dec. 11 at 1:13 PM

$APRE wowbeen out for a very long time. The pumpers still here? This thing gonna RS again??? Oof

0 · Reply

NewsAndFilings Dec. 11 at 12:17 PM

Yesterday's Recap: $AREB Reports 65% Year-Over-Year Growth with Sports World Tulsa $APRE The Street Podcast & Private Placement $BLQC Launch of New Corporate Website, BLQCBuster.com $SIGL Converts Rare 3-month U.S. Patent Victory for Analog Guard(R)

0 · Reply

TezBunny Dec. 11 at 8:50 AM

$APRE let’s hold this under a dollar ready for the next leg down

0 · Reply

NewsAndFilings Dec. 10 at 5:09 PM

$APRE Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules https://www.globenewswire.com/news-release/2025/12/09/3202351/0/en/Aprea-Therapeutics-Announces-3-1-Million-Private-Placement-Priced-At-The-Market-Under-Nasdaq-Rules.html

0 · Reply

NewsAndFilings Dec. 10 at 4:51 PM

Aprea Therapeutics (NASDAQ: $APRE) CEO Oren Gilad Reveals Oncology Breakthroughs on “The Street Reports Podcast” — Listen Now! https://thestreetreports.com/aprea-therapeutics-nasdaq-apre-ceo-oren-gilad-reveals-oncology-breakthroughs-on-the-street-reports-podcast-listen-now/

0 · Reply

MsGrumpy Dec. 10 at 4:25 PM

$APRE Aprea Therapeutics (NASDAQ: APRE) “The Street Reports Podcast” https://thestreetreports.com/aprea-therapeutics-nasdaq-apre-ceo-oren-gilad-reveals-oncology-breakthroughs-on-the-street-reports-podcast-listen-now/

0 · Reply

Market Cap	6.66M
Revenue (ttm)	1.50M
Net Income (ttm)	-12.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-864.00%
Debt to Equity Ratio	0.00

Volume	24,100
Avg Vol	100,346
Day's Range	N/A - N/A
Shares Out	6.99M
Stochastic %K	61%
Beta	1.23
Analysts	Strong Sell
Price Target	$8.67